Skin Necrosis in a Patient with Factor V Leiden Mutation following Nipple Sparing Mastectomy : Plastic and Reconstructive Surgery – Global Open

Journal Logo

Case Report

Skin Necrosis in a Patient with Factor V Leiden Mutation following Nipple Sparing Mastectomy

Bingol, Ugur Anil MD; Cinar, Can MD

Author Information
Plastic and Reconstructive Surgery - Global Open: October 2015 - Volume 3 - Issue 10 - p e529
doi: 10.1097/GOX.0000000000000512
  • Open
  • Turkey

Abstract

Since 2000, nipple-sparing mastectomy (NSM) and immediate breast reconstruction have replaced radical surgical interventions for the treatment of selected patients with breast cancer. NSM is technically a difficult procedure. After dissection, the remaining breast skin and nipple-areola complex (NAC) must be thin enough to be free of tumor tissue and thick enough to preserve tissue perfusion. Partial or total NAC necrosis is among the most common complications of NSM and negatively affects cosmetic results.1

Factor V Leiden (FVL) mutation is the most common cause of hereditary thrombophilia; thrombosis almost always develops in the venous system. The literature includes only a few case series of arterial thrombosis. The present study aimed to describe for the first time a patient with FVL mutation that developed NAC and skin necrosis, and multiple embolisms in the upper extremity arteries following NSM.

CLINICAL REPORT

A 61-year-old woman underwent NSM and prophylactic mastectomy of the left breast due to a 3-cm invasive ductal carcinoma in the right breast. During the same surgical session, the right breast was reconstructed using a tissue expander and the left breast was reconstructed using a breast prosthesis. No complications occurred during the intraoperative or postoperative periods, and the patient was discharged 2 days post surgery.

Follow-up 5 days post surgery showed bullae formation in the lateral pillar of the right breast and NAC of the right and left breasts. The bullae were aspirated and the wounds were dressed. The patient presented to the emergency department on postoperative day 7 due to the sensation of cold in the left hand and numbness and cyanosis in the first and second digits. A radial pulse was not present. The patient underwent magnetic resonance angiography, which showed thrombus in the subclavian artery and radial artery (Figs. 1, 2). The patient was admitted to the department of vascular surgery for further follow-up.

F1-15
Fig. 1:
Magnetic resonance angiography. Arrow shows thrombus in the subclavian artery.
F2-15
Fig. 2:
Brachial, ulnar, and radial arteries. * Radial artery cut-off point.

During 10 days of follow-up in the department of vascular surgery, bullous skin areas developed full-thickness skin necrosis and full-thickness necrosis developed at the incision lines (Fig. 3). The patient responded to medical therapy and circulation in the hand improved; therefore, vascular surgery was not scheduled. Following demarcation of the areas of full-thickness necrosis, the necrotic areas were excised and removed. Hematology consultation due to thrombus formation showed that the patient had an FVL mutation. The patient was then administered low-molecular-weight heparin during and after chemotherapy. Following radiotherapy, the patient was scheduled for implantation of left breast prosthesis and NAC reconstruction of both breasts.

F3-15
Fig. 3:
Full-thickness necrosis developed in the lateral pillar of the right breast, NAC of the right and left breasts, and at the incision lines.

DISCUSSION

NAC necrosis is among the most common complications following breast reconstruction.1 Superficial skin loss can recover spontaneously, whereas full-thickness skin loss can result in infection and prosthesis loss. Smoking, incision type, flap thickness, obesity, and preoperative irradiation are the most common risk factors for loss of breast skin.1,2

FVL mutation—an autosomal dominant mutation—is the most common hereditary cause of thrombophilia and accounts for 40–50% of all cases of hereditary hemophilia. The incidence of heterozygous mutation in Caucasians is 5–8% and is associated with a 3- to 7-fold increase in the risk of thrombosis.3–53–53–5 The incidence of homozygous mutation is 0.18%6 and is associated with an 80-fold increase in the risk of venous thromboembolism (VTE).7 FVL mutation was first described by Bertina et al8 in 1994. As a result of FVL mutation, arginine at amino acid position 506 in the factor V protein is substituted by glutamine. This substitution inactivates activated protein C and decelerates factor V inactivation, which results in a tendency for thrombosis due to over activation of the coagulation cascade9(Fig. 4).

F4-15
Fig. 4:
Coagulation cascade.

Thrombosis is almost always limited to the venous system in individuals harboring FVL mutation and thrombosis is most commonly observed in deep veins. Thrombosis in some cases is accompanied by pulmonary embolism. In addition to deep vein thrombosis and pulmonary embolism, cerebral, mesenteric, and portal vein thrombosis have also been reported.10–1210–1210–12 There is a debate over arterial thrombosis, and data on thrombosis of the hepatic artery,13 retinal artery,14 popliteal artery,15 and brachial artery16 are limited to just a few case reports. Studies have reported a weak but controversial association with myocardial infarction, particularly in patients aged <45 years.17,18 In patients with heterozygous FVL mutation, environmental factors act in tandem with hereditary factors in the development of thrombosis.19 Thrombus formation has many triggers, including pregnancy, smoking, use of oral contraceptives, surgery, cancer, and immobilization. The presented patient continued smoking during the early postoperative period, ignoring the recommendation to stop. The presented patient’s history of cancer and surgical trauma—both significant risk factors—in addition to a history of smoking might have triggered arterial thrombosis along with NAC necrosis.

The diagnosis of FVL mutation is established based on genetic testing; however, such testing is not routinely performed in all patients during the preoperative period. Female patients should be asked about problems experienced during pregnancy and history of miscarriage.20 Late pregnancy loss and pulmonary embolism—with or without deep venous thrombosis in the legs—are the most well-known complications. The presented patient reported 3 late-term pregnancy losses; subsequently, history of pregnancy and miscarriage is investigated extensively in all female patients who present to our outpatient clinic and are scheduled for surgery.

CONCLUSIONS

FVL mutation is the most common cause of thrombophilia. Without external factors (cancer, smoking, trauma, oral contraceptives, etc.), thromboembolic events are rare in FVL heterozygote individuals. Before scheduling patients for a long surgery or cancer surgery, a history of deep vein thrombosis or pulmonary embolism in young patients and miscarriage history in young females may provide clues to the surgeon for conditions as FVL mutation, which cannot be detected by simple laboratory tests during the preoperative period. In the absence of known risk factors, unexplained skin necrosis, and arterial thromboembolism or VTE during the postoperative period should increase the index of suspicion of FVL mutation.

REFERENCES

1. Algaithy ZK, Petit JY, Lohsiriwat V, et al. Nipple sparing mastectomy: can we predict the factors predisposing to necrosis? Eur J Surg Oncol. 2012;38:125–129
2. Colwell AS, Tessler O, Lin AM, et al. Breast reconstruction following nipple-sparing mastectomy: predictors of complications, reconstruction outcomes, and 5-year trends. Plast Reconstr Surg. 2014;133:496–506
3. Rees DC, Cox M, Clegg JB.. World distribution of factor V Leiden. Lancet. 1995;346:1133–1134
4. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706–708
5. Hillarp A, Zöller B, Svensson PJ, et al. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78:990–992
6. Kjellberg U, van Rooijen M, Bremme K, et al. Factor V Leiden mutation and pregnancy-related complications. Am J Obstet Gynecol. 2010;203:469.e1–469.e8
7. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood. 1995;85:1504–1508
8. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
9. De Stefano V, Leone G.. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica. 1995;80:344–356
10. Stolz E, Kemkes-Matthes B, Pötzsch B, et al. Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis. Acta Neurol Scand. 2000;102:31–36
11. Ağaoğlu N, Mustafa NA, Türkyilmaz S.. Prothrombotic disorders in patients with mesenteric vein thrombosis. J Invest Surg. 2003;16:299–304
12. El-Karaksy H, El-Koofy N, El-Hawary M, et al. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol. 2004;83:712–715
13. Fan J, Nishida S, Selvaggi G, et al. Factor V Leiden mutation is a risk factor for hepatic artery thrombosis in liver transplantation. Transplant Proc. 2013;45:1990–1993
14. Rishi P, Rishi E, Sharma T, et al. Hemi-central retinal artery occlusion in young adults. Indian J Ophthalmol. 2010;58:425–432
15. Page C, Rubin LE, Gusberg RJ, et al. Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: importance of synergistic factors. J Vasc Surg. 2005;42:1014–1018
16. Broxterman KJ, Mathew P, Chicoine L.. Left brachial artery thrombus, left axillary vein thrombus, and stroke in a neonate with factor V Leiden mutation. J Pediatr Hematol Oncol. 2000;22:472–475
17. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006;367:651–658
18. Mannucci PM, Asselta R, Duga S, et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. J Thromb Haemost. 2010;8:2116–2121
19. Rosén SB, Sturk A.. Activated protein C resistance–a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem. 1997;35:501–516
20. Rey E, Kahn SR, David M, et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361:901–908
© 2015 American Society of Plastic Surgeons